If you work in formulation or manufacturing, you know that probiotic products can be some of the most challenging supplements to develop and scale. You are not just building a tablet, capsule or powder that meets a specification. You are trying to protect living organisms while ensuring colony-forming unit (CFU) label claims are met at the end of expiry. That makes probiotic stability a constant balancing act between product performance, process efficiency, cost and compliance. It is therefore important to understand how blending, compression, powder flow and packaging can support probiotic stability, culture viability and shelf life.
Top five stability challenges in probiotic formulation and manufacturing
1. Sensitivity to environmental conditions
One of the biggest frustrations with probiotics is how quickly viability can be lost when environmental conditions are not tightly controlled. Moisture, heat, oxygen and light all work against stability, whether it’s during ingredient handling, processing or storage. For formulation scientists, this means building a system that protects sensitive strains without compromising performance. For manufacturing teams, it means managing exposure during production and preventing variability from one batch to the next. Oxygen-sensitive strains (i.e. Anaerobic bacteria) such as Bifidobacterium add another layer of complexity because even short-term exposure can affect survival.
To address this, stability needs to be designed in from the start through careful ingredient selection and characterisation. Some organisms are naturally more tolerant of heat, oxygen and moisture than others, and choosing strains with stronger processing resilience can reduce downstream risk, simplify scale-up and lessen the burden on the rest of the formulation and packaging system. Spore-forming probiotics such as Bacillus species can also offer improved stability compared with more traditional lactic acid bacteria because they are better able to withstand harsh environmental conditions.
2. Manufacturing stress
The manufacturing process can be where a promising probiotic formulation starts to lose performance. Compression forces, shear during blending, transfer steps and drying conditions can all damage cells before the product ever reaches the pack. Scientists often have to work within narrow process windows, where small changes in force, dwell time, temperature or humidity can affect CFU recovery. This can make scale-up challenging, as conditions that worked at bench or pilot scale do not always translate cleanly into routine production.
The solution is to build robust, protective processes around the organism. Drying technologies such as freeze-drying can preserve cell structure and viability by removing moisture under low temperatures, while optimised spray drying can provide a more cost-effective large-scale alternative when paired with protective carriers. Adding cryoprotectants or stabilisers such as trehalose during drying can help protect cell membranes and proteins, and tightly controlled manufacturing conditions with low humidity and temperature can potentially reduce premature degradation throughout processing.
3. Ingredient interactions
Formulation scientists must determine excipient compatibility and ingredient interactions that are not always obvious early in development. High water activity materials can tigger metabolic activity and rapid death, minerals or actives may create an unfavourable microenvironment, and some functional ingredient can undermine probiotic survival over time. The challenge is not simply choosing ingredients that process well—it is selecting a formulation system that protects viability while still delivering the intended product profile. This is where formulation optimisation becomes critical. Using low-moisture, low water activity excipients, adjusting the pH microenvironment and screening ingredient compatibility early can all help reduce stability risks.
Microencapsulation can provide an additional layer of protection by surrounding probiotic cells with polymers, lipids or polysaccharides to shield them from moisture, oxygen and other destabilising influences during processing and storage, while also supporting survival through the gastrointestinal tract.
4. Shelf life and supply chain conditions
Temperature fluctuations during transportation or improper storage conditions in retail environments can lead to significant CFU decline. If refrigeration is required, it can limit market accessibility and increase logistical costs. Controlled storage and transport conditions remain important, but the industry is increasingly moving towards shelf-stable formulations that reduce dependence on cold chain logistics and improve convenience for both manufacturers and consumers.
Humidity is also a major pathway to degradation. Protective packaging also plays a central role and should be considered early in the development process. High-barrier blister packs with aluminium foil, HDPE bottles with desiccants and oxygen scavengers, and unit-dose formats can all help minimise exposure to moisture and oxygen throughout shelf life.
5. Regulatory and label claims
Manufacturers must ensure that the labelled CFU count is met at the end of shelf life, not just at the time of manufacture. This often requires overages, which increase formulation costs and variability. Demonstrating stability through robust testing is essential for compliance and consumer trust. A practical response is to combine carefully modelled overages with strong accelerated and real-time stability programs so degradation rates are better understood, and formulations can be optimised with greater confidence. As predictive modelling tools improve, manufacturers are gaining better ways to estimate shelf life, reduce excessive overages and support more reliable label claim compliance.
Final thoughts
For formulation and manufacturing scientists, probiotic stability is rarely a single-variable problem. It is the result of many interconnected decisions across strain selection, process design, excipient choice, packaging and supply chain control. The pressure to deliver viable counts at the end of shelf life—while keeping processes efficient, scalable and commercially realistic—makes this one of the more complex areas in nutraceutical development.
In Part 2, we will present a detailed case study featuring Lactobacillus acidophilus, illustrating how probiotic viability was significantly enhanced by employing a strategic blend of core excipients alongside innovative desiccant packaging solutions.
